Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CancerFLCloneSeq

Financiado

Clone-based full-length RNA-seq for early diagnosis of cancer

Intra-tumor genetic heterogeneity imposes a great challenge on cancer therapy. Resistance to molecularly targeted therapies and chemotherapy can arise from selective growth of pre-existing sub-clones that carries drug-resistance m... ver más

31/05/2024

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MultiCloneSeq Single-Clone Multi-omics Sequencing for Cancer Diagnosis 150K€ Cerrado

RTC2019-006918-1 DESARROLLO DE UNA PLATAFORMA DINAMICA DE DETECCION RAPIDA DE... 407K€ Cerrado

ONCOTRACK OncoTrack - Methods for systematic next generation oncology... 31M€ Cerrado

SAF2017-87811-R MUTACIONES QUE AFECTAN A LA MADURACION DEL RNA Y MUTACIONES... 200K€ Cerrado

EQC2018-005144-P Plataforma de genómica para secuenciación de célula única y... 168K€ Cerrado

PTQ2021-011652 Investigación y desarrollo de herramientas para la detección... 70K€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2022-08-09
Fecha Fin: 2024-05-31

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Intra-tumor genetic heterogeneity imposes a great challenge on cancer therapy. Resistance to molecularly targeted therapies and chemotherapy can arise from selective growth of pre-existing sub-clones that carries drug-resistance mutations, altered metabolic and/or epigenomic states, providing a survival advantages. Early detection of these subclonal states can thus significantly aid cancer therapy. However, attempts to profile various types of primary cancer cells using single-cell techniques are relatively poor. One of the major limitations is the significant dropout rate (i.e., loss of alleles) observed in single-cell RNA-seq. It severely affects our ability to leverage single cell RNA-seq to accurately profile somatic mutation, to reveal cancer driver mutation and even extract low/mid-level expressed genes and splicing. For that reason, most of the efforts to expose mutations that are critical for cancer growth and can subsequently lead to more effective treatment are based on the sequencing of bulk populations. However, due to the noise introduced by PCR, sequencing and alignment processes, bulk sequencing is limited to identify mutations with a frequency higher than 5%. Here we propose to develop a novel 3D clone-based full-length RNA-seq profiling technology. A preliminary version of this technology for digital profiling of mRNA, already allowed us to significantly improve sensitivity comparing to gold-standard single-cell RNA-seq methods. Using this preliminary version on clones of lung adenocarcinoma, we revealed novel cancer stem like subpopulation that could not be detected using regular single cell RNA-seq maps. Altogether, improving the ability to detect rare mutations (<5%), splicing events and transcriptional variation between cancer cells, will be an extremely powerful tool for early diagnosis of cancer and effective means to improve personalized based drug treatment decision making.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores